Market research
PAB.AU Patrys Limited
AU AUD Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- 0.13
- Dividend yield
- Not available
- Beta
- 1.25
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Not available
- Industry
- Not available
- ISIN
- AU000000PAB9
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- 0.13
- Dividend yield
- Not available
- Beta
- 1.25
About
About Patrys Limited
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is based in Nedlands, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PAB.AU discussion.
5 years, 5 months ago
Patrys Limited is currently in a long term uptrend where the price is trading 93.3% above its 200 day moving average.
From a valuation standpoint, the stock is 296.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1019.8.
Patrys Limited's total revenue rose by 78.1% to $215K since the same quarter in the previous year.
Its net income has dropped by 17.2% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 76.3% to $-778K since the same quarter in the previous year.
Based on the above factors, Patrys Limited gets an overall score of 2/5.